安宫牛黄丸治疗CAR-T相关细胞因子释放 综合征
Treatment of CAR-T-Associated Cytokine Release Syndrome with Angong Niuhuang Pill
DOI: 10.12677/acm.2026.163926, PDF,   
作者: 李素芳:云南中医药大学第一临床医学院,云南 昆明;李慧园*:云南省第一人民医院血液内科,云南 昆明
关键词: 安宫牛黄丸CAR-T细胞治疗恶性血液病细胞因子释放综合征Angong Niuhuang Pill CAR-T Cell Therapy Hematologic Malignancies Cytokine Release Syndrome
摘要: 安宫牛黄丸是中医经典急救用药,具有清热解毒、镇惊开窍的功效。嵌合抗原受体T (chimeric antigen receptor T, CAR-T)细胞治疗通过基因修饰T细胞使其能够靶向并杀伤异常细胞。CAR-T细胞治疗已成为恶性血液病治疗的重要手段。经过CAR-T细胞治疗,患者生存周期明显延长。CAR-T细胞治疗在为患者带来新的生机时刻,也带来了一系列副作用,常见的包括细胞因子释放综合征(Cytokine Release Syndrome, CRS)、免疫效应细胞相关的神经毒性(Immune effector cell-associated neurotoxicity syndrome, ICANS)、慢性移植物抗宿主病(GVHD)。本文介绍1例安宫牛黄丸治疗CAR-T相关细胞因子释放综合征。
Abstract: Angong Niuhuang Pill is a classic first-aid medicine in traditional Chinese medicine, with the effects of clearing away heat and detoxifying, calming convulsions and inducing resuscitation. Chimeric antigen receptor T (CAR-T) cell therapy modifies T cells genetically to enable them to target and kill abnormal cells. CAR-T cell therapy has become an important treatment for hematologic malignancies, and the survival cycle of patients has been significantly prolonged after receiving this therapy. While bringing new hope to patients, CAR-T cell therapy also causes a series of adverse effects, commonly including Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and chronic Graft-Versus-Host Disease (GVHD). This article reports one case of Angong Niuhuang Pill in the treatment of CAR-T-associated cytokine release syndrome.
文章引用:李素芳, 李慧园. 安宫牛黄丸治疗CAR-T相关细胞因子释放 综合征[J]. 临床医学进展, 2026, 16(3): 1455-1459. https://doi.org/10.12677/acm.2026.163926

参考文献

[1] 李雪丽, 郑恩琪, 白雪. 基于“矿物-有机”成分互作机制的安宫牛黄丸质量控制与安全性评价研究进展[J]. 中国药物警戒, 2025, 22(12): 1340-1344+1351.
[2] 白雪, 陈亚飞, 唐田, 等. 安宫牛黄丸临床应用与药理机制研究进展[J]. 中国药物警戒, 2025, 22(3): 349-356.
[3] 何阿娜, 夏梦贝, 彭英, 等. 安宫牛黄丸中11种主要成分含量测定及大鼠体内暴露研究 [J]. 药学学报, 2025, 60(8): 2585-2594.
[4] 饶小平, 邬涛, 蔡丹. 安宫牛黄丸对儿童心肺复苏后脑电图及血清BNP、S100β、NSE的影响[J]. 辽宁中医杂志, 2025, 52(11): 86-89.
[5] 中国医药教育协会. 安宫牛黄丸临床应用专家共识[J]. 中国中西医结合杂志, 2022, 42(8): 933-946.
[6] 沈晓圆, 许冠华, 沈建军, 等. 安宫牛黄丸对热射病患者热休克蛋白70及炎症因子的影响[J]. 全科医学临床与教育, 2020, 18(12): 1091-1094.
[7] Davila, M.L., Bouhassira, D.C.G., Park, J.H., Curran, K.J., Smith, E.L., Pegram, H.J., et al. (2014) Chimeric Antigen Receptors for the Adoptive T Cell Therapy of Hematologic Malignancies. International Journal of Hematology, 99, 361-371. [Google Scholar] [CrossRef] [PubMed]
[8] 任禹珂, 屈哲, 霍桂桃, 等. CAR-T细胞治疗相关细胞因子释放综合征的研究进展[C]//中国毒理学会药物毒理与安全性评价专业委员会. 2025年(第十三届)药物毒理学年会论文摘要汇编. 中国食品药品检定研究院安全评价研究所, 药品监管科学全国重点实验室, 北京市重点实验室, 细胞及基因治疗药物质量和非临床研究与评价北京市重点实验室, 2025: 385-386.
[9] Liu, Q., Zhou, Y. and Yang, Z. (2016) The Cytokine Storm of Severe Influenza and Development of Immunomodulatory Therapy. Cellular & Molecular Immunology, 13, 3-10. [Google Scholar] [CrossRef] [PubMed]
[10] Iovino, L., Thur, L.A., Gnjatic, S., Chapuis, A., Milano, F. and Hill, J.A. (2021) Shared Inflammatory Pathways and Therapeutic Strategies in COVID-19 and Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 9, e002392. [Google Scholar] [CrossRef] [PubMed]
[11] Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., et al. (2018) Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 378, 439-448. [Google Scholar] [CrossRef] [PubMed]
[12] 朱清玉, 刘家云, 龙铟. 中草药在缓解及治疗细胞因子释放综合征中的作用[J]. 中药材, 2025, 48(8): 2124-2129.